Once-yearly jab for HIV protection passes first trial hurdle
Michelle Roberts Digital health editor, BBC News Getty Images An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops the virus from replicating inside cells. If future trials go well – now it has passed the first, Phase … Read more